Get started
Author

Carlo Maurea

The Emerging Issue of Cardiac Dysfunction Induced by Antineoplastic Angiogenesis Inhibitors
2013 · Carlo G. Tocchetti, Giuseppina Gallucci, et al. · European Journal of Heart Failure · 73
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
2016 · Gennaro Riccio, Carmela Coppola, et al. · Human Vaccines & Immunotherapeutics · 59
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
2018 · Gennaro Riccio, Salvatore Antonucci, et al. · Frontiers in Physiology · 50
PDF
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
2023 · Vincenzo Quagliariello, Irma Bisceglia, et al. · Cancers · 48
PDF
Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
2024 · V. Quagliariello, M. L. Canale, et al. · Frontiers in Cardiovascular Medicine · 46
In the Era of Cardiovascular–Kidney–Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy
2025 · Vincenzo Quagliariello, Massimiliano Berretta, et al. · Cancers · 35
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
2016 · Carmela Coppola, Gennaro Riccio, et al. · OncoTargets and Therapy · 33
PDF
Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19.
2021 · V Quagliariello, A Paccone, et al. · PubMed · 30
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
2024 · V. Quagliariello, M. Passariello, et al. · Frontiers in Cardiovascular Medicine · 28
PDF
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients
2024 · Vincenzo Quagliariello, Maria Laura Canale, et al. · International Journal of Molecular Sciences · 22
Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?
2022 · Vincenzo Quagliariello, Manuela Giovanna Basilicata, et al. · Journal of Cardiovascular Development and Disease · 19
PDF
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
2024 · Vincenzo Quagliariello, Massimiliano Berretta, et al. · Cancers · 17
PDF
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition
2025 · Vincenzo Quagliariello, Massimiliano Berretta, et al. · International Journal of Molecular Sciences · 11
PDF
Cardio–Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity
2025 · Vincenzo Quagliariello, Annabella Di Mauro, et al. · Antioxidants · 11
Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism
2024 · Vincenzo Quagliariello, Maria Laura Canale, et al. · Biomedicines · 5
Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients
2025 · Vincenzo Quagliariello, Massimiliano Berretta, et al. · Journal of Cardiovascular Pharmacology · 4
Cardioprotective and anti-inflammatory effects of empagliflozin during treatment with doxorubicin: A cellular and preclinical study
2019 · V. Quagliariello, C. Coppola, et al. · Annals of Oncology · 4
LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model
2017 · N. Maurea, R. Paciello, et al. · Annals of Oncology · 4
Cardiotoxic effects of the novel anti-ErbB2 agent ado trastuzumab emtansine
2016 · R.V. Iaffaioli, C. Coppola, et al. · Annals of Oncology · 4
Effect of anti CTLA-4 and PD-1 monoclonal antibodies on systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models.
2024 · Martina Iovine, Vincenzo Quagliariello, et al. · Journal of Clinical Oncology · 3
PDF
C12 Dapagliflozin Increases Pampk and Reduces Myocardial and Renal Nf–kb Expression in Preclinical Models of Short–term Doxorubicin Cardiotoxicity Through Myd–188 and Nlrp3 Pathways
2023 · V Quagliariello, A Paccone, et al. · European Heart Journal Supplements · 3
PDF
51 Palmitoylethanolamide associated to polydatin reduces inflammation in human endothelial vascular cells exposed to doxorubicin and trastuzumab through PPAR-a and NLRP3-related pathways
2021 · Vincenzo Quagliariello, Martina Iovine, et al. · European Heart Journal Supplements · 2
Ranolazine after doxorubicin treatment: Cardioprotective effects in vitro and in vivo.
2016 · Nicola Maurea, Carmela Coppola, et al. · Journal of Clinical Oncology · 2
Retrospective analysis of a tertiary care centre of sex differences in risk factors, aetiology and short-term clinical outcome after revascularization treatment in young adults’ ischemic stroke
2024 · Rosaria Renna, Gionata Spagnoletti, et al. · Neurological Sciences · 1
2312P SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
2023 · A. Bonelli, M.L. Canale, et al. · Annals of Oncology · 1
PDF
Works count: 62
Citation count: 524
H-index: 12
I10-index: 14
Year
Topic
Type